While the prevalence of kidney stones among men older than 60 remained stable during this time period, the prevalence of kidney stones in women ages 20 to 39 nearly doubled between 2007 and 2013 (3.9 to 7.5 percent)
FDA grants accelerated approval to semaglutide (Wegovy) for MASH On Aug 15, 2025, the FDA approved Wegovy (semaglutide) injection for adults with MASH with moderate-to-advanced fibrosis, under the accelerated approval (See FDA announcement below.) The following is a summary of clinical trial data for resmetirom and semaglutide
doi:10.3233/JPD-2011-11023 Abdul HM, Calabrese V, Calvani M, Butterfield DA (2006) Acetyl-l-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimers disease
Role of ferroptosis in chronic kidney disease
No extra fees
Ensuring you receive maximum benefit from your coverage, we clarify options and eligibility, even exploring manufacturer savings programs for those without coverage